Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

JANX008

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Janux Therapeutics

Drug class:

EGFR inhibitor, T-cell stimulant, CD3 modulator

Related drugs:

‹

cetuximab (347)

osimertinib (301)

erlotinib (235)

gefitinib (194)

panitumumab (123)

lapatinib (107)

neratinib (102)

brigatinib (50)

aumolertinib (39)

amivantamab-vmjw (25)

furmonertinib (14)

mobocertinib (12)

lazertinib (12)

tarloxotinib bromide (7)

nimotuzumab (6)

rociletinib (5)

tomuzotuximab (4)

necitumumab (3)

befotertinib (3)

ABP 494 (cetuximab biosimilar) (1)

BAY 2927088 (1)

Compound 6a (1)

abivertinib (1)

STI-001 (cetuximab biosimilar) (0)

antroquinonol (0)

zalutumumab (0)

JNJ-26483327 (0)

PF-08046052 (0)

rindopepimut (0)

Undisclosed EGFR inhibitor (0)

cetuximab biosimilar (0)

PF-06747775 (0)

JNJ-64041757 (0)

naptumomab estafenatox (0)

CD30 biAb-AATC (0)

activated T-lymphocytes (0)

NEO_PLIN2101 (0)

darleukin/fibromun (0)

TAC100-HER2 (0)

TCRT-ESO-A2 (0)

tabelecleucel (0)

UMG2-CD3 BTCE (0)

›